A LinkedIn post from Castelion highlights comments by co-founder and CFO Andrew Kreitz, CFA, in a Nasdaq “Live from MarketSite” segment with Kristina Ayanian. According to the post, Kreitz described 2026 as a year focused on testing, development, and preparing for potential production in 2027 following what is characterized as the largest Series B in defense tech history.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post indicates three main priorities for 2026: completing development of Blackbeard, described as Castelion’s first hypersonic weapons system, building out “Project Ranger,” a 1,000-acre scaled production site, and accelerating work on a larger, longer-range system. These initiatives suggest that recent funding may be directed toward transitioning from R&D to scaled manufacturing capabilities in the defense sector.
For investors, the emphasis on hypersonic weapons and large-scale production infrastructure points to a capital-intensive growth phase with a multiyear horizon before potential revenue from full-scale production. If Castelion executes on these milestones and converts development programs into production contracts, its position within the emerging hypersonic defense market could strengthen, though timelines and contract visibility remain key uncertainties.
The linkage to Nasdaq programming may also signal an effort to increase visibility among capital markets audiences, even though Castelion remains a private company. Overall, the post suggests a strategic focus on building industrial capacity and expanding the product roadmap, developments that could influence the company’s valuation and competitive standing in defense technology over the next several years.